National Journal Club - November 2024

Register
- Member - Tier I - Free!
- Member - Tier II - Free!
- Member - Tier III - Free!
- Member - Tier IV - Free!
Continue

The Use of GLP-1 Agonists for Substance Use Disorders

Presented by: Rutgers Health/New Jersey Medical School

Articles:

Qeadan F, McCunn A, Tingey B: The association between glucose-dependent insulinotropic polypeptide and / or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders : A real-world data analysis. Addiction 2024;1-15.Wan
Wang W, Volkow ND, Berger NA, et al: Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. Molec Psych 2024;29:2587-2598.
Wang W, Volkow ND, Wang Q, et al: Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder. JAMA Network Open 2024;7(9):e2435247

Series Moderator: Steven E. Aks, DO, FACEP, FACMT, Toxikon Consortium

About The Series: ACMT's National Journal Club (NJC) is a bimonthly member webinar hosted by a different fellowship program each session. All data and information provided in this activity is for informational purposes only. ACMT makes no representations as to accuracy, completeness, currentness, suitability, or validity of the content and will not be liable for any errors or omissions in this information or any losses, injuries, or damages arising from its display or use.

This webinar is for ACMT members only.

Steven E. Aks, DO, FACMT (Moderator)

Toxicology Director and Professor of Emergency Medicine

Rush Medical College

Dr. Steven Aks graduated from the New York Institute of Technology College of Osteopathic Medicine in 1987. He works in Chicago, IL and 4 other locations and specializes in Public Health & General Preventive Medicine, Emergency Medicine and Medical Toxicology. Dr. Aks is affiliated with John H Stroger Jr Hospital Of Cook County.